KDIGO 2022 Clinical Practice Guideline FOR the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease

TY - JOUR

T1 - KDIGO 2022 Clinical Practice Guideline FOR the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease

AU - Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group

AU - Jadoul, M.

AU - Awan, A. A.

AU - Berenguer, M. C.

AU - Bruchfeld, A.

AU - Fabrizi, F.

AU - Goldberg, D. S.

AU - Jia, J.

AU - Kamar, N.

AU - Mohamed, R.

AU - Pessôa, M. G.

AU - Pol, S.

AU - Sise, M. E.

AU - Martin, P.

N1 - Funding Information: Fabrizio Fabrizi, MD, is associate director and professor of nephrology at Maggiore Policlinico Hospital and IRCCS Cà Granda Foundation, Milan, Italy. His research focuses on the understanding of the epidemiology, natural history, and treatment of viral hepatitis (HBV and HCV) in patients with CKD. He has performed clinical trials, narrative or systematic reviews, and laboratory-based studies. He has received grants from the Italian Society of Nephrology and research fellowships from the Society of Italian-American Nephrologists as support for his research. Dr. Fabrizi has actively participated in the development of several national/international guidelines concerning the management of viral hepatitis in CKD patients, including the inaugural 2008 KDIGO HCV guideline. He currently serves on the editorial board of many journals, including the International Journal of Artificial Organs, Cancer, Journal of Nephrology, and Pathogens. He has authored more than 300 publications in peer-reviewed journals, such as Kidney International, the American Journal of Kidney Diseases, and the Clinical Journal of the American Society of Nephrology, among others. Funding Information: Dr. Goldberg is a transplant hepatologist who dedicates most of his time to conducting epidemiology and health services research on topics related to chronic and end-stage liver disease, organ allocation and transplantation, and organ donation. He is currently the principal investigator (PI)/Co-PI of two R01 grants funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)/NIH focused on developing new models to estimate the survival benefit of liver transplantation and to develop better models to predict outcomes of kidney and liver allografts; a U01 from the NIDDK to perform a multi-center trial of transplanting kidneys from hepatitis C-infected donors into hepatitis C-negative patients; and a U01 to participate in the NIDDK-sponsored Liver Cirrhosis Network. Dr. Goldberg has published more than 150 peer-reviewed publications including first-author papers in the New England Journal of Medicine and JAMA, and was the first author of the first trial focused on transplanting kidneys from hepatitis C-infected donors into hepatitis C-negative recipients followed by antiviral treatment.

PY - 2022/12

Y1 - 2022/12

UR - https://www.scopus.com/pages/publications/85141525400

U2 - 10.1016/j.kint.2022.07.013

DO - 10.1016/j.kint.2022.07.013

M3 - Article

C2 - 36410841

AN - SCOPUS:85141525400

SN - 0085-2538

VL - 102

SP - S129-S205

JO - Kidney International

JF - Kidney International

IS - 6

ER -